StayCurrentMD · Efficacy, Safety and Predictive Factors for Outcomes and Adverse Events in Sclerotherapy for Venous Malformations in Children
Article1 min read·Published Oct 2025

Efficacy, Safety and Predictive Factors for Outcomes and Adverse Events in Sclerotherapy for Venous Malformations in Children

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Oct 2025 · 1 min read

In brief

In brief

This study evaluates polidocanol sclerotherapy outcomes in pediatric patients with venous malformations, addressing a gap in pediatric-specific data. The research examines treatment efficacy, safety profiles, and identifies predictive factors for both successful outcomes and adverse events in this young population.

  • Percutaneous sclerotherapy is an established treatment for venous malformations but pediatric data remain limited.
  • This study evaluates polidocanol-based sclerotherapy efficacy and safety specifically in children with venous malformations.
  • The research identifies predictive factors for both clinical outcomes and adverse events in pediatric sclerotherapy patients.
  • Polidocanol is the sclerosing agent of choice, requiring outcome data to optimize pediatric treatment protocols.

Written by the GCMD Library team from the article.

Percutaneous sclerotherapy is an established treatment for venous malformations (VM), while data on its use in children remain limited. This study aimed to evaluate the efficacy, safety and predictors of clinical outcome and adverse events (AEs) in children undergoing polidocanol-based sclerotherapy of VMs.

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →